Study record
NMN, NAD⁺ metabolism, and arterial stiffness (2023)
Human RCT — biomarker endpoint
○ Evidence tier 4 — Human RCT — biomarker endpoint
Record verify: verified against primary source
| Design | Randomized, double-blind, placebo-controlled trial (biomarker) |
| DOI | 10.1038/s41598-023-29787-3 |
| Citation status | doi verified via Crossref 2026-07-12 (Sci Rep 2023;13, 'Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial'). PMID and trial registry ID are not confirmed; see identifier status. |
Identifiers: DOI verified; PMID not reported; trial registry id not reported. Record-level verification and identifier-level status are separate: a record can be verified against its primary publication on one identifier while another is simply not confirmed. No identifier is fabricated, and none is left in a “pending” state.
Five-qualifier claim
| Species / population | Middle-aged and older adults (randomized, placebo-controlled trial). |
| Exposure, route, schedule | Oral NMN (long-term supplementation) over the trial period. |
| Comparator / duration | Placebo-controlled, double-blind, randomized. |
| Endpoint / numeric result | Changes in NAD+ metabolism and an arterial-stiffness measure after long-term NMN supplementation. |
| What it did NOT establish | Biomarker/surrogate vascular endpoints — no functional-disability, disease-outcome, or lifespan endpoint. |
Interventions
Primary reference
https://doi.org/10.1038/s41598-023-29787-3
Exact identifier confirmed against the primary record via Crossref/ClinicalTrials.gov where stated in the citation status names the source and the date. An identifier that is not confirmed is named as such in the identifier row above, never filled in from a secondary source.